Alpha-1 antitrypsin - Kamada
Alternative Names: A1AT; A1PI; AAT; AAT-IH; AAT-IV; Alpha-1 Antitrypsin; Alpha-1-Antiproteinase; alpha-1-proteinase inhibitor; ALPHA.1-PROTEINASE INHIBITOR HUMAN; Aralast; D1-AAT; G1-AAT; G1-AAT IV; GLASSIA; Glassia; Infinia; Inhaled-AAT; IV AAT; Kamada-API; L1-AAT; Prolastin-CLatest Information Update: 27 Mar 2025
At a glance
- Originator Kamada
- Developer Kamada; Mount Sinai Hospital (Toronto); Takeda
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Enzymes; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Alpha 1-antitrypsin deficiency
- Discontinued Bronchiectasis; Cystic fibrosis; Graft-versus-host disease; Lung transplant rejection; Type 1 diabetes mellitus
Most Recent Events
- 27 Mar 2025 Alpha-1 antitrypsin - Kamada is available for licensing as of 31 Dec 2024 https://www.kamada.com/
- 08 Jan 2025 Kamada receives positive feedback from US FDA for its phase III InnovAATe trial
- 15 May 2024 Kamada anticipates a feedback from the US FDA regarding a revised Statistical Analysis Plan (SAP) and study protocol of the phase III InnovAATe trial, by 2H of 2024